Niowave and Novartis (NOVN SW) enter global actinium-225 supply agreement to advance next-generation cancer therapies

Niowave's agreement with Novartis underscores a strategic move in the pharmaceutical sector towards enhancing cancer treatment options.

Newsquawk StaffPublished On the live feed at 6 more headlines followed before this page went public
Newsquawk headlinesUTC

Ford (F) recorded around USD 13.8bln of charges in Q4 related to updated EV strategy and expected disposition of the BOSK investment

QXO (QXO) to purchase Kodiak Building Partners for c. USD 2.2bln; The transaction is expected to be highly accretive to 2026 earnings and will expand QXO’s current addressable market to more than USD 200bln

Niowave and Novartis (NOVN SW) enter global actinium-225 supply agreement to advance next-generation cancer therapies

Humana (HUM) Q4 2025 (USD): adj. EPS -3.96 (exp. -4.00), Revenue 32.5bln (exp. 32.04bln)

Hilton Worldwide (HLT) Q4 2025 (USD): Adj. EPS 2.08 (exp. 2.02), Revenue 3.09bln (exp. 2.98bln), sees FY Adj. EPS 8.65-8.77 (exp. 9.13)

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

This could position Novartis favorably within the biotechnology landscape, potentially indicating a focus on innovative therapies that might attract investor interest and impact sector sentiment.

Related headlines

The whole workspace, free to try.

Try it free